Plasma Neurofilament Analysis in VITALITY-ALS

Evaluation of Aficamten in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4

Long-Term Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

ENCALS Predictive Survival Model in FORTITUDE-ALS

Sex Differences in Heart Failure with Reduced Ejection Fraction in the GALACTIC-HF Trial

Improvement in KCCQ Scores in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in the REDWOOD HCM OLE Study